知识与财富的链接
目的 探讨左西孟旦治疗肺动脉高压老年患者的临床疗效及安全性。方法 选取2019年6月～2020年5月于滨州市人民医院住院的肺功脉高压老年患者126例作为研究对象,根据治疗方案不同将其分为对照组(69例)和试验组(57例)。对照组患者给予吸氧,常规治疗肺部原发疾病;试验组患者在对照组治疗基础上,加用左西孟旦治疗。比较两组患者的近期疗效、生活质量、远期疗效和不良反应发生情况。结果 治疗1周后,两组患者的下肢周径、肺动脉压、脑钠肽(brain natriuretic peptide,BNP)均显著低于本组治疗前(均P<0.05),24h尿量、动脉血氧分压(arterial partial pressure of oxygen,PaO2)均显著高于本组治疗前(均P<0.05);试验组患者的下肢周径、肺动脉压、BNP均显著低于对照组(均P<0.05),24h尿量、PaO2均显著高于对照组(均P<0.05)。出院后1个月,两组患者的6min步行距离均显著长于本组治疗前(均P<0.05),明尼苏达心力衰竭生活质量问卷(Minnesota living with hear...
Objective To investigate the clinical efficacy and safety of levosimendan in elderly patients with pulmo-nary hypertension. Methods A total of 126 elderly patients with pulmonary hypertension hospitalized in Binzhou People''s Hospital from June 2019 to May 2020 were selected, and they were divided into control group (69 cases) and experimental group (57 cases) according to different treatment plans. The control group received oxygen inhalation and routine treatment of primary lung disease and the experimental group was treated with levosimendan on the basis of control group. The short–term efficacy, quality of life, long–term efficacy and incidence of adverse reactions were compared between the two groups. Results After one week of treatment, lower limb circumference, pulmonary artery pressure, brain natriuretic peptide (BNP) in two groups were significantly lower than before treatment (all P<0.05), 24h urine volume, arterial partial pressure of oxygen (PaO2) were significantly higher than before treatment (all P<0.05). Lower limb circumference, pulmonary artery pressure and BNP in experimental group were significantly lower than those in control group (all P<0.05), 24h urine volume and PaO2 were significantly higher than those in control group (all P<0.05). One month after discharge, 6min walking distance in both groups was significantly longer than before treatment (P<0.05), Minnesota living with heart failure questionnaire (MLHFQ) score was significantly lower than before treatment (P<0.05). The 6min walking distance of experimental group was significantly longer than that of control group (P<0.05), and the MLHFQ score was significantly lower than that of control group (P<0.05).The readmission rate in experimental group was significantly lower than that in control group (χ2 =6.100, P=0.014). The main adverse reactions in experimental group were hypotension (5.3%, 3/57) and arrhythmia (3.5%, 2/57), and there was no significant difference in the incidence of adverse events between the two groups (χ2 =3.704, P=0.054). Conclusion Levosimendan treating elderly patients with pulmonary hypertension caused by pulmonary disease and hypoxemia can effectively improve their clinical symptoms, reduce pulmonary artery pressure and improve their qual-ity of life, with a low incidence of adverse reactions and high safety
